Cargando…
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044304/ https://www.ncbi.nlm.nih.gov/pubmed/33867925 http://dx.doi.org/10.3389/fnins.2021.647783 |
_version_ | 1783678455473242112 |
---|---|
author | Bellomo, Giovanni Indaco, Antonio Chiasserini, Davide Maderna, Emanuela Paolini Paoletti, Federico Gaetani, Lorenzo Paciotti, Silvia Petricciuolo, Maya Tagliavini, Fabrizio Giaccone, Giorgio Parnetti, Lucilla Di Fede, Giuseppe |
author_facet | Bellomo, Giovanni Indaco, Antonio Chiasserini, Davide Maderna, Emanuela Paolini Paoletti, Federico Gaetani, Lorenzo Paciotti, Silvia Petricciuolo, Maya Tagliavini, Fabrizio Giaccone, Giorgio Parnetti, Lucilla Di Fede, Giuseppe |
author_sort | Bellomo, Giovanni |
collection | PubMed |
description | Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a critical factor when defining cut-off values. The calculation of cut-off values is often influenced by the composition of AD and control groups. Indeed, the clinically defined AD group may include patients affected by other forms of dementia, while the control group is often very heterogeneous due to the inclusion of subjects diagnosed with other neurological diseases (OND). In this context, unsupervised machine learning approaches may overcome these issues providing unbiased cut-off values and data-driven patient stratification according to the sole distribution of biomarkers. In this work, we took advantage of the reproducibility of automated determination of the CSF core AD biomarkers to compare two large cohorts of patients diagnosed with different neurological disorders and enrolled in two centers with established expertise in AD biomarkers. We applied an unsupervised Gaussian mixture model clustering algorithm and found that our large series of patients could be classified in six clusters according to their CSF biomarker profile, some presenting a typical AD-like profile and some a non-AD profile. By considering the frequencies of clinically defined OND and AD subjects in clusters, we subsequently computed cluster-based cut-off values for Aβ42/Aβ40, p-tau, and t-tau. This approach promises to be useful for large-scale biomarker studies aimed at providing efficient biochemical phenotyping of neurological diseases. |
format | Online Article Text |
id | pubmed-8044304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80443042021-04-15 Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders Bellomo, Giovanni Indaco, Antonio Chiasserini, Davide Maderna, Emanuela Paolini Paoletti, Federico Gaetani, Lorenzo Paciotti, Silvia Petricciuolo, Maya Tagliavini, Fabrizio Giaccone, Giorgio Parnetti, Lucilla Di Fede, Giuseppe Front Neurosci Neuroscience Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a critical factor when defining cut-off values. The calculation of cut-off values is often influenced by the composition of AD and control groups. Indeed, the clinically defined AD group may include patients affected by other forms of dementia, while the control group is often very heterogeneous due to the inclusion of subjects diagnosed with other neurological diseases (OND). In this context, unsupervised machine learning approaches may overcome these issues providing unbiased cut-off values and data-driven patient stratification according to the sole distribution of biomarkers. In this work, we took advantage of the reproducibility of automated determination of the CSF core AD biomarkers to compare two large cohorts of patients diagnosed with different neurological disorders and enrolled in two centers with established expertise in AD biomarkers. We applied an unsupervised Gaussian mixture model clustering algorithm and found that our large series of patients could be classified in six clusters according to their CSF biomarker profile, some presenting a typical AD-like profile and some a non-AD profile. By considering the frequencies of clinically defined OND and AD subjects in clusters, we subsequently computed cluster-based cut-off values for Aβ42/Aβ40, p-tau, and t-tau. This approach promises to be useful for large-scale biomarker studies aimed at providing efficient biochemical phenotyping of neurological diseases. Frontiers Media S.A. 2021-03-31 /pmc/articles/PMC8044304/ /pubmed/33867925 http://dx.doi.org/10.3389/fnins.2021.647783 Text en Copyright © 2021 Bellomo, Indaco, Chiasserini, Maderna, Paolini Paoletti, Gaetani, Paciotti, Petricciuolo, Tagliavini, Giaccone, Parnetti and Di Fede. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Bellomo, Giovanni Indaco, Antonio Chiasserini, Davide Maderna, Emanuela Paolini Paoletti, Federico Gaetani, Lorenzo Paciotti, Silvia Petricciuolo, Maya Tagliavini, Fabrizio Giaccone, Giorgio Parnetti, Lucilla Di Fede, Giuseppe Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders |
title | Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders |
title_full | Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders |
title_fullStr | Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders |
title_full_unstemmed | Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders |
title_short | Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders |
title_sort | machine learning driven profiling of cerebrospinal fluid core biomarkers in alzheimer’s disease and other neurological disorders |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044304/ https://www.ncbi.nlm.nih.gov/pubmed/33867925 http://dx.doi.org/10.3389/fnins.2021.647783 |
work_keys_str_mv | AT bellomogiovanni machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT indacoantonio machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT chiasserinidavide machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT madernaemanuela machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT paolinipaolettifederico machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT gaetanilorenzo machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT paciottisilvia machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT petricciuolomaya machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT tagliavinifabrizio machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT giacconegiorgio machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT parnettilucilla machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders AT difedegiuseppe machinelearningdrivenprofilingofcerebrospinalfluidcorebiomarkersinalzheimersdiseaseandotherneurologicaldisorders |